ABUS Arbutus Biopharma Corporation - Common Stock
$5.01
가격 · 8월 19, 2026
기준 재무 정보 8월 12, 2026
52주 범위
$3–$5
82% of range
애널리스트 평점
BUY
8 analysts
목표 주가
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
순이익률
-237.9%
Arbutus Biopharma Corporation - Common Stock 정보 위키백과 회사 개요
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
더 보기
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
ABUS 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$5.01
시가총액
$987M
P/E (TTM)
-30.1
EPS (TTM)
$-0.17
매출 (TTM)
$14M
배당 수익률
—
ROE
-42.0%
부채/자본
—
52주 범위
$3 – $5
ABUS 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$14M
2016-12-31
→
2025-12-31
EPS
$-0.17
2016-12-31
→
2025-12-31
잉여현금흐름
$-40M
2016-12-31
→
2025-12-31
마진
-237.9%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
ABUS
동종업계 중앙값
P/E (TTM)
-30.1
6.7
P/S (TTM)
70.1
39.8
P/B
12.9
4.8
Price / FCF (주가 / FCF)
-24.9
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
ABUS
동종업계 중앙값
Operating Margin (영업이익률)
-271.0%
—
Net Profit Margin (순이익률)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
ABUS
동종업계 중앙값
Current Ratio (유동비율)
15.7
9.7
Quick Ratio (당좌 비율)
15.5
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
ABUS
동종업계 중앙값
Revenue YoY (매출 YoY)
128.2%
—
Revenue CAGR 3Y (매출 CAGR 3년)
-28.8%
—
Revenue CAGR 5Y (매출 CAGR 5년)
15.3%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
ABUS
동종업계 중앙값
ABUS 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
8 명의 애널리스트
- 적극 매수 3 37.5%
- 매수 4 50.0%
- 보유 1 12.5%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
1 명의 애널리스트 · 2026-08-17
저가
$5.53
고가
$5.53
중앙값 목표
$5.53
+10.3%
평균 목표
$5.53
+10.3%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
0.01%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 3월 31일 | $-0.05 | $-0.03 | -0.02% |
| 2025년 12월 31일 | $-0.02 | $-0.04 | 0.02% |
| 2025년 9월 30일 | $-0.04 | $-0.03 | -0.01% |
| 2025년 6월 30일 | $0.01 | $-0.05 | 0.06% |
| 2025년 3월 31일 | $-0.13 | $-0.11 | -0.02% |
| 2024년 12월 31일 | $-0.07 | $-0.08 | 0.01% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
대차대조표 25
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
현금 흐름 14
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
유동성 및 지급능력 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
효율성 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
대차대조표 22
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
현금 흐름 11
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
유동성 및 지급능력 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
가치 평가 (TTM) 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $14M | $6M | $18M | $39M | $11M |
| 영업이익률 % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| 순이익 | $-34M | $-70M | $-73M | $-69M | $-76M |
| 희석 EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| 당좌 비율 | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-40M | $-65M | $-87M | $-36M | $-68M |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 191개의 제출자 · $496.0M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 41 (+9 이전 분기 대비) | 23 (-7 이전 분기 대비) | 55 (+10 이전 분기 대비) | 44 (-9 이전 분기 대비) | +5.4M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| Two Seas Capital LP | $91,658,798 | 19,095,583 | 18.48% | 주식 |
| Whitefort Capital Management, LP | $75,812,453 | 15,794,261 | 15.28% | 주식 |
| VANGUARD GROUP INC | $38,412,670 | 7,986,002 | 7.74% | 주식 |
| STATE STREET CORP | $37,772,059 | 7,869,179 | 7.62% | 주식 |
| Rubric Capital Management LP | $36,158,098 | 7,532,937 | 7.29% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33,651,259 | 7,010,679 | 6.78% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $16,983,987 | 3,537,471 | 3.42% | 주식 |
| BlackBarn Capital Partners LP | $12,000,000 | 2,500,000 | 2.42% | 주식 |
| Woodline Partners LP | $10,952,909 | 2,281,856 | 2.21% | 주식 |
| GOLDMAN SACHS GROUP INC | $8,545,829 | 1,780,381 | 1.72% | 주식 |
| Jefferies Financial Group Inc. | $8,216,026 | 1,711,672 | 1.66% | 주식 |
| NOMURA HOLDINGS INC | $7,857,989 | 1,637,081 | 1.58% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7,398,998 | 1,541,458 | 1.49% | 주식 |
| BANK OF AMERICA CORP /DE/ | $7,169,851 | 1,493,719 | 1.45% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6,869,846 | 1,431,218 | 1.38% | 주식 |
| OSAIC HOLDINGS, INC. | $6,469,756 | 1,347,866 | 1.30% | 주식 |
| ADAR1 Capital Management, LLC | $6,087,106 | 1,268,147 | 1.23% | 주식 |
| Deltroit Asset Management (UK) LLP | $5,760,000 | 1,200,000 | 1.16% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $5,449,738 | 1,135,362 | 1.10% | 주식 |
| CITIGROUP INC | $4,175,784 | 869,955 | 0.84% | 주식 |
| BANK OF MONTREAL /CAN/ | $3,734,102 | 777,938 | 0.75% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3,123,360 | 650,700 | 0.63% | 주식 |
| MACKENZIE FINANCIAL CORP | $2,946,269 | 613,806 | 0.59% | 주식 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2,889,638 | 602,008 | 0.58% | 주식 |
| Western Standard LLC | $2,605,378 | 542,787 | 0.53% | 주식 |
| Rangeley Capital, LLC | $2,400,000 | 500,000 | 0.48% | 주식 |
| Man Group plc | $2,272,642 | 473,467 | 0.46% | 주식 |
| Corbin Capital Partners, L.P. | $2,231,732 | 682,487 | 0.45% | 주식 |
| CenterBook Partners LP | $2,136,725 | 445,151 | 0.43% | 주식 |
| Freestone Capital Holdings, LLC | $2,124,000 | 442,500 | 0.43% | 주식 |
| CITADEL ADVISORS LLC | $1,942,541 | 404,696 | 0.39% | 주식 |
| KENNEDY CAPITAL MANAGEMENT LLC | $1,849,430 | 385,298 | 0.37% | 주식 |
| Swiss National Bank | $1,375,200 | 286,500 | 0.28% | 주식 |
| Ledgewood Wealth Advisors, LLC | $1,336,493 | 278,436 | 0.27% | 주식 |
| FMR LLC | $1,277,232 | 266,090 | 0.26% | 주식 |
| Susquehanna Portfolio Strategies, LLC | $1,265,688 | 263,685 | 0.26% | 주식 |
| Carrera Capital Advisors | $1,234,402 | 257,167 | 0.25% | 주식 |
| Quinn Opportunity Partners LLC | $1,225,027 | 255,214 | 0.25% | 주식 |
| D. E. Shaw & Co., Inc. | $1,209,614 | 252,003 | 0.24% | 주식 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,161,682 | 242,017 | 0.23% | 주식 |
| Campbell & CO Investment Adviser LLC | $1,106,563 | 230,534 | 0.22% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,080,475 | 225,099 | 0.22% | 주식 |
| Squarepoint Ops LLC | $999,096 | 208,145 | 0.20% | 주식 |
| MARTINGALE ASSET MANAGEMENT L P | $926,880 | 193,100 | 0.19% | 주식 |
| RHUMBLINE ADVISERS | $909,224 | 189,423 | 0.18% | 주식 |
| STRS OHIO | $810,720 | 168,900 | 0.16% | 주식 |
| Bank of New York Mellon Corp | $801,067 | 166,889 | 0.16% | 주식 |
| Caption Management, LLC | $720,000 | 150,000 | 0.15% | 콜 옵션 |
| Caption Management, LLC | $720,000 | 150,000 | 0.15% | 풋 옵션 |
| Hudson Bay Capital Management LP | $720,000 | 150,000 | 0.15% | 주식 |
| Wealth Management Associates, Inc. | $710,376 | 147,995 | 0.14% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $701,467 | 146,139 | 0.14% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643,433 | 142,985 | 0.13% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $631,080 | 140,240 | 0.13% | 주식 |
| Connor, Clark & Lunn Investment Management Ltd. | $619,685 | 129,101 | 0.12% | 주식 |
| BlackRock, Inc. | $567,398 | 118,208 | 0.11% | 주식 |
| Front Row Advisors LLC | $516,035 | 110,500 | 0.10% | 주식 |
| BARCLAYS PLC | $499,320 | 104,025 | 0.10% | 주식 |
| Rafferty Asset Management, LLC | $490,416 | 102,170 | 0.10% | 주식 |
| MetLife Investment Management, LLC | $452,885 | 94,351 | 0.09% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $429,994 | 89,582 | 0.09% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $407,933 | 84,986 | 0.08% | 주식 |
| JBF Capital, Inc. | $385,349 | 80,281 | 0.08% | 주식 |
| Integrated Quantitative Investments LLC | $383,698 | 79,937 | 0.08% | 주식 |
| Virtus Investment Advisers, LLC | $368,674 | 76,807 | 0.07% | 주식 |
| XTX Topco Ltd | $365,808 | 76,210 | 0.07% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $317,832 | 66,215 | 0.06% | 주식 |
| Invesco Ltd. | $305,616 | 63,670 | 0.06% | 주식 |
| Rockefeller Capital Management L.P. | $302,400 | 63,000 | 0.06% | 주식 |
| Creative Planning | $298,133 | 62,111 | 0.06% | 주식 |
| JANUS HENDERSON GROUP PLC | $273,746 | 60,900 | 0.06% | 주식 |
| Quantinno Capital Management LP | $273,413 | 56,961 | 0.06% | 주식 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265,118 | 55,233 | 0.05% | 주식 |
| Vanguard Global Advisers, LLC | $264,730 | 55,152 | 0.05% | 주식 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255,936 | 53,320 | 0.05% | 주식 |
| Jump Financial, LLC | $255,178 | 53,162 | 0.05% | 주식 |
| PROFUND ADVISORS LLC | $254,482 | 53,017 | 0.05% | 주식 |
| WOLVERINE TRADING, LLC | $248,868 | 55,800 | 0.05% | 콜 옵션 |
| Police & Firemen's Retirement System of New Jersey | $248,203 | 51,709 | 0.05% | 주식 |
| Exome Asset Management LLC | $240,797 | 50,166 | 0.05% | 주식 |
| Magnetar Financial LLC | $225,922 | 47,067 | 0.05% | 주식 |
| State of New Jersey Common Pension Fund D | $221,602 | 46,167 | 0.04% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212,664 | 44,305 | 0.04% | 주식 |
| ALLSTATE CORP | $212,285 | 44,226 | 0.04% | 주식 |
| Quadrature Capital Ltd | $201,619 | 42,004 | 0.04% | 주식 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189,475 | 39,474 | 0.04% | 주식 |
| ARIZONA STATE RETIREMENT SYSTEM | $189,110 | 39,398 | 0.04% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175,680 | 36,600 | 0.04% | 콜 옵션 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171,936 | 35,820 | 0.03% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $169,286 | 35,268 | 0.03% | 주식 |
| INTECH INVESTMENT MANAGEMENT LLC | $167,208 | 34,835 | 0.03% | 주식 |
| Mitsubishi UFJ Trust & Banking Corp | $152,102 | 31,688 | 0.03% | 주식 |
| VOYA INVESTMENT MANAGEMENT LLC | $151,070 | 31,473 | 0.03% | 주식 |
| China Universal Asset Management Co., Ltd. | $150,902 | 31,438 | 0.03% | 주식 |
| Vanguard Investments Australia, Ltd. | $150,182 | 31,288 | 0.03% | 주식 |
| KLP KAPITALFORVALTNING AS | $148,320 | 30,900 | 0.03% | 주식 |
| Premier Path Wealth Partners, LLC | $144,000 | 30,000 | 0.03% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $139,675 | 29,099 | 0.03% | 주식 |
| SHERBROOKE PARK ADVISERS LLC | $134,627 | 27,989 | 0.03% | 주식 |
| EntryPoint Capital, LLC | $134,112 | 27,940 | 0.03% | 주식 |
회사 내부자 25 명의 내부자 · 13 임원 · 11 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 2019년 6월 24일 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 2019년 3월 1일 A | 341,396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 2019년 3월 1일 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 2017년 3월 24일 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 2019년 3월 1일 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 2019년 3월 1일 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 2019년 3월 1일 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 2019년 3월 1일 A | 1,503,403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 2018년 12월 11일 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 2018년 4월 16일 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 2017년 3월 24일 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 2016년 8월 16일 M | 42,097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 2016년 3월 15일 A | — | 0 | 0 | $0 |
| Roger Sawhney | 이사 | 2026년 6월 8일 A | — | 0 | 0 | $0 |
| Robert A Beardsley | 이사 | 2026년 6월 8일 A | — | 0 | 0 | $0 |
| Frank Torti | 이사 | 2018년 11월 26일 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | 이사 | 2018년 6월 19일 A | — | 0 | 0 | $0 |
| Keith S Manchester | 이사 | 2018년 6월 19일 A | — | 0 | 0 | $0 |
| Daniel D Burgess | 이사 | 2018년 6월 19일 A | — | 0 | 0 | $0 |
| Herbert J Conrad | 이사 | 2018년 6월 19일 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | 이사 | 2018년 6월 19일 A | 1,000 | 0 | 0 | $0 |
| Frank Karbe | 이사 | 2017년 6월 21일 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | 10% 소유주 | 2021년 10월 18일 C | 38,847,462 | 0 | 0 | $0 |
| Andrew Lo | 10% 소유주 | 2018년 1월 12일 P | — | 0 | 0 | $0 |
| Patrick Machado | 10% 소유주 | 2018년 1월 12일 P | — | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 8 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 제출 서류 | 2026년 4월 28일 | 8.00% | 수정본 | — | SEC |
| Roivant Sciences Ltd. ×14 제출 서류 | 2025년 2월 25일 | 20.50% | 수정본 | — | SEC |
| Patrick Machado ×4 제출 서류 | 2019년 7월 17일 | — | 최초 제출 | — | SEC |
| Dr. Andrew Lo ×5 제출 서류 | 2019년 7월 17일 | — | 최초 제출 | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 제출 서류 | 2019년 7월 12일 | — | 최초 제출 | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 제출 서류 | 2019년 7월 12일 | — | 최초 제출 | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 제출 서류 | 2019년 7월 12일 | — | 최초 제출 | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 제출 서류 | 2019년 7월 12일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 34 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.66% | 58,600 NS | 2026년 4월 30일 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.11% | 132,235 NS | 2026년 4월 30일 | N-PORT |
| BIB · ProShares Trust | 0.04% | 7,110 NS | 2026년 5월 31일 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.03% | 64,366 NS | 2026년 5월 31일 | N-PORT |
| RSSL · Global X Funds | 0.02% | 65,520 NS | 2026년 4월 30일 | N-PORT |
| ITWO · ProShares Trust | 0.02% | 7,126 NS | 2026년 5월 31일 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 734,401 NS | 2026년 5월 31일 | N-PORT |
| UWM · ProShares Trust | 0.01% | 5,554 NS | 2026년 5월 31일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 64,437 NS | 2026년 4월 30일 | N-PORT |
| URTY · ProShares Trust | 0.01% | 5,639 NS | 2026년 5월 31일 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 5,309 NS | 2026년 5월 31일 | N-PORT |
| HDG · ProShares Trust | 0.00% | 141 NS | 2026년 5월 31일 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 86,163 NS | 2026년 5월 31일 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.00% | 4,760 NS | 2026년 5월 31일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026년 7월 15일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026년 7월 15일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 2026년 7월 15일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 2026년 7월 15일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 2026년 7월 15일 | 일간 |
| ITOT · iShares Trust | — | — | 2026년 7월 22일 | 일간 |
| IWV · iShares Trust | — | — | 2026년 8월 18일 | 일간 |
| IWO · iShares Trust | — | — | 2026년 8월 18일 | 일간 |
| IWM · iShares Trust | — | — | 2026년 8월 18일 | 일간 |
| IBB · iShares Trust | — | — | 2026년 8월 18일 | 일간 |
| IWC · iShares Trust | — | — | 2026년 8월 18일 | 일간 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026년 7월 13일 | 일간 |
| VHT · VANGUARD WORLD FUND | — | — | 2026년 7월 20일 | 일간 |
| ISCB · iShares Trust | — | — | 2026년 7월 20일 | 일간 |
| ISCG · iShares Trust | — | — | 2026년 7월 21일 | 일간 |
| ISCV · iShares Trust | — | — | 2026년 7월 20일 | 일간 |
| SMMV · iShares Trust | — | — | 2026년 8월 18일 | 일간 |
| WSML · iShares Trust | — | — | 2026년 7월 20일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | 2026년 7월 20일 | 일간 |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 2026년 7월 20일 | 일간 |